American CryoStem Corp. :CRYO-US: Earnings Analysis: Q3, 2017 By the Numbers : August 23, 2017

American CryoStem Corp. reports financial results for the quarter ended June 30, 2017.

We analyze the earnings along side the following peers of American CryoStem Corp. – Brainstorm Cell Therapeutics Inc., Verastem, Inc., Arrowhead Pharmaceuticals, Inc., Fate Therapeutics, Inc. and Caladrius Biosciences, Inc. (BCLI-US, VSTM-US, ARWR-US, FATE-US and CLBS-US) that have also reported for this period.


  • Summary numbers: Revenues of USD 0.43 million, Net Earnings of USD 0.01 million.
  • Gross margins widened from 33.49% to 64.88% compared to the same period last year, operating (EBITDA) margins now 12.31% from -176.38%.
  • Year-on-year change in operating cash flow of 157.93% is about the same as the change in earnings, likely no significant movement in accruals or reserves.
  • Earnings growth from operating margin improvements as well as one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30
Relevant Numbers (Quarterly)
Revenues (mil) 0.43 0.43 0.32 0.16 0.16
Revenue Growth (%YOY) 172.48 205.95 130.37 13.58 47.66
Earnings (mil) 0.01 -0.01 -0.09 -1.36 -0.32
Earnings Growth (%YOY) 103.64 91.16 -30.73 -64.81 -107.88
Net Margin (%) 2.67 -2.86 -29.57 -871.22 -199.71
EPS 0 -0 -0 -0.04 -0.01
Return on Equity (%) N/A N/A N/A N/A N/A
Return on Assets (%) 5.93 -7.21 -62.49 -967.72 -249.63

Access our Ratings and Scores for American CryoStem Corp.

Market Share Versus Profits

Revenues History
Earnings History

CRYO-US‘s change in revenue this period compared to the same period last year of 172.48% is almost the same as its change in earnings, and is about average among the announced results thus far in its peer group, suggesting that CRYO-US is holding onto its market share. Also, for comparison purposes, revenues changed by 0.50% and earnings by 193.70% compared to the immediate last period.

Revenues Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Leader, Earnings Focus, Laggard, Revenues Focus

Earnings Growth Analysis

The company’s earnings growth was influenced by year-on-year improvement in gross margins from 33.49% to 64.88% as well as better cost controls. As a result, operating margins (EBITDA margins) rose from -176.38% to 12.31% compared to the same period last year. For comparison, gross margins were 62.58% and EBITDA margins were 9.18% in the last reporting period.

Gross Margin Versus EBITDA Margin

Quadrant label definitions. Hover to know more

Differentiated; Low Cost, Commodity; Low Cost, Commodity; High Cost, Differentiated; High Cost

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

CRYO-US‘s gross margin improvement has not produced any big difference in its working capital. Working capital days are currently -466.40, compared to last year’s level of -772.13 days. This leads Capital Cube to conclude that the improvements in gross margins are likely from operating decisions and not trade-offs with the balance sheet.

Gross Margin Versus Working Capital Days

Quadrant label definitions. Hover to know more

Customer Financed, Cash Starved, Supplier Financed, Cash Rich

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

CRYO-US‘s change in operating cash flow of 157.93% compared to the same period last year is about the same as its change in earnings this period. Additionally, this change in operating cash flow is about average among its peer group. This suggests that the company did not use accruals or reserves to manage earnings this period, and that, all else being equal, the earnings number is sustainable.

Operating Cash Flow Growth Versus Earnings Growth

Quadrant label definitions. Hover to know more

Cash Flow based Earnings, Likely Non-cash Earnings, Low Cash Flow Base, Likely Undeclared Earnings


The company’s earnings growth has also been influenced by the following factors: (1) Improvements in operating (EBIT) margins from -182.62% to 10.06% and (2) one-time items. The company’s pretax margins are now 2.67% compared to -199.71% for the same period last year.

EBIT Margin Versus PreTax Margin

Quadrant label definitions. Hover to know more

Operation driven Earnings, One-time Favorables, Low Earnings Base, One-time Unfavorables
EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for American CryoStem Corp.

Company Profile

American CryoStem Corp. engages in the development, market, and licenses patented adipose tissue-based cellular technologies, bio-materials, and related proprietary services. It focuses on clinical processing, commercial bio-banking, and application development for adipose tissue and adipose-derived stem cells; and also provides contract manufacturing services to physicians and other medical professionals that perform tissue transfer and other cellular therapy services, as well as offers professional services, including sterility, viability, cellular density, and growth assay analysis. The company was founded by Anthony Francis Dudzinski on November 18, 2008 and is headquartered in Eatontown, NJ.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of CRYO-US.